Prescribing of Brimonidine Tartrate 3mg/g Gel (Mirvaso®) is not supported

Thurrock CCG and Basildon and Brentwood CCG do not support the prescribing of brimonidine tartrate 3mg/g gel (Mirvaso®) as it is considered to be a cosmetic product.

Mirvaso® contains the active ingredient brimonidine tartrate 3mg/g and is licensed for symptomatic treatment of facial erythema of rosacea in adult patients. It achieves this by direct vasoconstriction of superficial peripheral blood vessels.

Its use is considered to be cosmetic in nature and therefore Mirvaso® is not recommended for prescribing.

For further information please refer to the East of England Priorities Advisory Committee guidance statement January 2015.

PAC – Brimonidine gel

Providers commissioned to provide services on behalf of Thurrock CCG and Basildon and Brentwood CCG are reminded that they are required to follow the local joint formulary and prescribing guidance, or relevant Medicines Management agreement.